Symbols / CVKD
CVKD Chart
About
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 18.21M |
| Enterprise Value | 10.07M | Income | -14.39M | Sales | — |
| Book/sh | 1.33 | Cash/sh | 1.86 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -1.44 | PEG | — |
| P/S | — | P/B | 5.87 | P/C | — |
| EV/EBITDA | -0.69 | EV/Sales | — | Quick Ratio | 2.86 |
| Current Ratio | 3.02 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -8.72 | EPS next Y | -5.42 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-10 06:00 | ROA | -209.23% |
| ROE | -4.68% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.34M |
| Shs Float | 1.61M | Short Float | 3.87% | Short Ratio | 1.35 |
| Short Interest | — | 52W High | 22.90 | 52W Low | 4.91 |
| Beta | 1.21 | Avg Volume | 58.02K | Volume | 199.82K |
| Target Price | $35.00 | Recom | Strong_buy | Prev Close | $6.71 |
| Price | $7.79 | Change | 16.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$35.00
Mean price target
2. Current target
$7.79
Latest analyst target
3. DCF / Fair value
$-50.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.79
Low
$25.00
High
$45.00
Mean
$35.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-11-11 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-06-06 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2023-12-18 | init | Noble Capital Markets | — → Outperform | $4 |
| 2023-11-20 | init | HC Wainwright & Co. | — → Buy | $3 |
- $CVKD stock is up 17% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 19
- HIT trial: CAD-1005 patients had 50% clot rate vs >75% on placebo - Stock Titan ue, 24 Feb 2026 13
- Cadrenal Highlights Mixed Phase 2 Results for CAD-1005 - TipRanks ue, 24 Feb 2026 14
- Cadrenal Therapeutics Announces Phase 2 Results For CAD-1005 - TradingView ue, 24 Feb 2026 13
- Cadrenal Therapeutics stock surges on Phase 2 trial results - Investing.com South Africa ue, 24 Feb 2026 17
- Understanding the Setup: (CVKD) and Scalable Risk - Stock Traders Daily Mon, 15 Dec 2025 08
- $CVKD stock is up 20% today. Here's what we see in our data. - Quiver Quantitative hu, 04 Dec 2025 08
- Cadrenal Therapeutics (NASDAQ: CVKD) builds multi-asset anticoagulation platform in $40B market - Stock Titan Fri, 12 Dec 2025 08
- Cadrenal Therapeutics Announces New Securities Purchase Agreement - TipRanks ue, 16 Dec 2025 08
- The Technical Signals Behind (CVKD) That Institutions Follow - Stock Traders Daily hu, 04 Dec 2025 08
- Cadrenal Therapeutics (Nasdaq: CVKD) adds Phase 2 12-LOX HIT therapy with FDA Fast Track - Stock Titan hu, 11 Dec 2025 08
- Technical Reactions to CVKD Trends in Macro Strategies - Stock Traders Daily ue, 11 Nov 2025 08
- Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion - Stock Titan Fri, 12 Dec 2025 08
- Cadrenal Therapeutics, Inc. Reports Q3 2025 Financial Results and Clinical Development Updates on Tecarfarin and Frunexian | CVKD Stock News - Quiver Quantitative Mon, 10 Nov 2025 08
- How a small biotech is building an emergency anticoagulation plan - Stock Titan ue, 30 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 9933 | 69233.0 | — | Sale at price 6.97 per share. | SZOT MATTHEW K | Chief Financial Officer | — | 2025-12-29 00:00:00 | D |
| 1 | 3600 | 50364.0 | — | Sale at price 13.99 per share. | SZOT MATTHEW K | Chief Financial Officer | — | 2025-10-27 00:00:00 | D |
| 2 | 2444 | 34237.0 | — | Sale at price 13.99 - 14.03 per share. | PHAM QUANG X | Chief Executive Officer | — | 2025-10-27 00:00:00 | D |
| 3 | 3493 | 49011.0 | — | Sale at price 13.99 - 14.07 per share. | SZOT MATTHEW K | Chief Financial Officer | — | 2025-10-13 00:00:00 | D |
| 4 | 3600 | 50706.0 | — | Sale at price 14.02 - 14.15 per share. | PHAM QUANG X | Chief Executive Officer | — | 2025-10-13 00:00:00 | D |
| 5 | 107 | 1497.0 | — | Sale at price 13.99 per share. | SZOT MATTHEW K | Chief Financial Officer | — | 2025-10-06 00:00:00 | D |
| 6 | 500 | 7065.0 | — | Sale at price 14.13 per share. | PHAM QUANG X | Chief Executive Officer | — | 2025-10-02 00:00:00 | D |
| 7 | 1800 | 25183.0 | — | Sale at price 13.99 - 14.00 per share. | SZOT MATTHEW K | Chief Financial Officer | — | 2025-10-01 00:00:00 | D |
| 8 | 1300 | 18213.0 | — | Sale at price 14.01 per share. | PHAM QUANG X | Chief Executive Officer | — | 2025-10-01 00:00:00 | D |
| 9 | 12400 | 174175.0 | — | Sale at price 14.00 - 14.05 per share. | SZOT MATTHEW K | Chief Financial Officer | — | 2025-09-25 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 |
| NormalizedEBITDA | -10.65M | -7.38M |
| TotalUnusualItems | 0.00 | -956.23K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -956.23K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.65M | -8.36M |
| ReconciledDepreciation | 1.88K | 1.98K |
| EBITDA | -10.65M | -8.34M |
| EBIT | -10.65M | -8.34M |
| NetInterestIncome | 309.25K | 231.99K |
| InterestExpense | 0.00 | 17.10K |
| InterestIncome | 309.25K | 249.09K |
| NormalizedIncome | -10.65M | -7.40M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.65M | -8.36M |
| TotalExpenses | 10.96M | 7.63M |
| TotalOperatingIncomeAsReported | -10.96M | -7.63M |
| DilutedAverageShares | 1.22M | 899.47K |
| BasicAverageShares | 1.22M | 899.47K |
| DilutedEPS | -8.73 | -9.29 |
| BasicEPS | -8.73 | -9.29 |
| DilutedNIAvailtoComStockholders | -10.65M | -8.36M |
| NetIncomeCommonStockholders | -10.65M | -8.36M |
| NetIncome | -10.65M | -8.36M |
| NetIncomeIncludingNoncontrollingInterests | -10.65M | -8.36M |
| NetIncomeContinuousOperations | -10.65M | -8.36M |
| PretaxIncome | -10.65M | -8.36M |
| OtherIncomeExpense | -956.23K | |
| SpecialIncomeCharges | 0.00 | -740.14K |
| OtherSpecialCharges | 740.14K | |
| GainOnSaleOfSecurity | -216.09K | |
| NetNonOperatingInterestIncomeExpense | 309.25K | 231.99K |
| InterestExpenseNonOperating | 0.00 | 17.10K |
| InterestIncomeNonOperating | 309.25K | 249.09K |
| OperatingIncome | -10.96M | -7.63M |
| OperatingExpense | 10.96M | 7.63M |
| DepreciationAmortizationDepletionIncomeStatement | 1.88K | 1.98K |
| DepreciationAndAmortizationInIncomeStatement | 1.88K | 1.98K |
| DepreciationIncomeStatement | 1.88K | 1.98K |
| ResearchAndDevelopment | 4.21M | 4.08M |
| SellingGeneralAndAdministration | 6.75M | 3.55M |
| GeneralAndAdministrativeExpense | 6.75M | 3.55M |
| OtherGandA | 6.75M | 3.55M |
| TotalRevenue | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 1.78M | 868.18K | 775.64K |
| ShareIssued | 1.78M | 868.18K | 775.64K |
| NetDebt | 564.48K | ||
| TotalDebt | 0.00 | 21.35K | 640.71K |
| TangibleBookValue | 7.44M | 7.69M | -5.55M |
| InvestedCapital | 7.44M | 7.69M | -4.95M |
| WorkingCapital | 7.43M | 7.67M | -606.88K |
| NetTangibleAssets | 7.44M | 7.69M | -5.55M |
| CapitalLeaseObligations | 0.00 | 21.35K | 43.64K |
| CommonStockEquity | 7.44M | 7.69M | -5.55M |
| TotalCapitalization | 7.44M | 7.69M | -5.00M |
| TotalEquityGrossMinorityInterest | 7.44M | 7.69M | -5.55M |
| StockholdersEquity | 7.44M | 7.69M | -5.55M |
| RetainedEarnings | -25.72M | -15.07M | -6.71M |
| AdditionalPaidInCapital | 33.16M | 22.76M | 1.15M |
| CapitalStock | 1.78K | 868.00 | 8.19K |
| CommonStock | 1.78K | 868.00 | 8.19K |
| PreferredStock | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 2.68M | 826.88K | 6.33M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 4.99M |
| DerivativeProductLiabilities | 0.00 | 4.38M | |
| NonCurrentAccruedExpenses | 0.00 | 40.21K | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 574.69K | |
| LongTermCapitalLeaseObligation | 0.00 | 21.35K | |
| LongTermDebt | 553.34K | ||
| CurrentLiabilities | 2.68M | 826.88K | 1.33M |
| CurrentDebtAndCapitalLeaseObligation | 21.35K | 66.02K | |
| CurrentCapitalLeaseObligation | 0.00 | 21.35K | 22.29K |
| CurrentDebt | 43.73K | ||
| CurrentNotesPayable | 0.00 | 43.73K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 966.58K | 596.13K | 605.29K |
| PayablesAndAccruedExpenses | 1.72M | 209.39K | 663.17K |
| CurrentAccruedExpenses | 214.91K | 42.08K | 258.27K |
| Payables | 1.50M | 167.32K | 404.90K |
| AccountsPayable | 1.50M | 167.32K | 404.90K |
| TotalAssets | 10.12M | 8.52M | 778.17K |
| TotalNonCurrentAssets | 10.74K | 27.08K | 50.58K |
| OtherNonCurrentAssets | 3.79K | 3.79K | 5.99K |
| NetPPE | 6.94K | 23.29K | 44.59K |
| GrossPPE | 6.94K | 23.29K | 44.59K |
| OtherProperties | 6.94K | 23.29K | 44.59K |
| CurrentAssets | 10.11M | 8.49M | 727.60K |
| CurrentDeferredAssets | 14.45K | 0.00 | 672.29K |
| PrepaidAssets | 42.26K | 52.42K | 22.71K |
| Receivables | 38.15K | 37.25K | |
| AccruedInterestReceivable | 38.15K | 37.25K | |
| CashCashEquivalentsAndShortTermInvestments | 10.02M | 8.40M | 32.59K |
| CashAndCashEquivalents | 10.02M | 8.40M | 32.59K |
| CashFinancial | 32.59K |
| Line Item | 2024-12-31 | 2023-12-31 |
|---|---|---|
| FreeCashFlow | -7.36M | -3.53M |
| RepaymentOfDebt | 0.00 | -250.00K |
| IssuanceOfDebt | 0.00 | |
| IssuanceOfCapitalStock | 5.14M | 11.90M |
| CapitalExpenditure | -6.54K | -3.25K |
| EndCashPosition | 10.02M | 8.40M |
| BeginningCashPosition | 8.40M | 32.59K |
| ChangesInCash | 1.62M | 8.37M |
| FinancingCashFlow | 8.98M | 11.90M |
| CashFlowFromContinuingFinancingActivities | 8.98M | 11.90M |
| NetOtherFinancingCharges | -878.66K | |
| ProceedsFromStockOptionExercised | 4.71M | 250.00K |
| NetCommonStockIssuance | 5.14M | 11.90M |
| CommonStockIssuance | 5.14M | 11.90M |
| NetIssuancePaymentsOfDebt | 0.00 | -250.00K |
| NetShortTermDebtIssuance | 0.00 | -250.00K |
| ShortTermDebtPayments | 0.00 | -250.00K |
| NetLongTermDebtIssuance | 0.00 | |
| LongTermDebtIssuance | 0.00 | |
| InvestingCashFlow | -6.54K | -3.25K |
| CashFlowFromContinuingInvestingActivities | -6.54K | -3.25K |
| NetPPEPurchaseAndSale | -6.54K | -3.25K |
| PurchaseOfPPE | -6.54K | -3.25K |
| OperatingCashFlow | -7.36M | -3.53M |
| CashFlowFromContinuingOperatingActivities | -7.36M | -3.53M |
| ChangeInWorkingCapital | 1.87M | 144.31K |
| ChangeInOtherWorkingCapital | -14.45K | 672.29K |
| ChangeInOtherCurrentAssets | 0.00 | 2.19K |
| ChangeInPayablesAndAccruedExpense | 1.88M | -463.22K |
| ChangeInAccruedExpense | 543.28K | -225.65K |
| ChangeInInterestPayable | 0.00 | |
| ChangeInPayable | 1.34M | -237.58K |
| ChangeInAccountPayable | 1.34M | -237.58K |
| ChangeInPrepaidAssets | 10.17K | -29.71K |
| ChangeInReceivables | -905.00 | -37.25K |
| OtherNonCashItems | -352.00 | 3.01M |
| StockBasedCompensation | 1.42M | 710.38K |
| DepreciationAmortizationDepletion | 1.88K | 1.98K |
| DepreciationAndAmortization | 1.88K | 1.98K |
| Depreciation | 1.88K | 1.98K |
| OperatingGainsLosses | 956.23K | |
| GainLossOnInvestmentSecurities | 216.09K | |
| NetIncomeFromContinuingOperations | -10.65M | -8.36M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CVKD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|